Millennium Initiates Combination Oncology Trials of MLN341 With Taxotere

Topics:
Healthcare Services,
Pharmeceuticals
Tags:
Agent,
Business Operations,
Millennium Pharmaceuticals Inc.,
Real Estate
Source:
Millennium Pharmaceuticals

FREE Registration is required

Overview: In this article Millennium Pharmaceuticals, Inc. discusses about the initiation of multiple phase I clinical trials of MLN341 (formerly LDP-341, PS-341), in combination with Taxotere (docetaxel) for Injection Concentrate, Aventis Pharmaceuticals' chemotherapy agent used in the treatment of some breast and lung cancers. The clinical studies are being conducted to assess the safety of MLN341 in combination with the commonly used cancer agent in advanced solid tumors. MLN341, the first investigational drug candidate in a new class of anti-cancer agents, is a small molecule proteasome inhibitor under development by Millennium as a novel potential therapy to treat human malignancies.

(Is this item miscategorized? Does it need more tags? Let us know.)

Format: HTML | Date: Jan 2002 | Pages: 4

People who downloaded this item also downloaded

Case Study Intel Solution Services Offers Sutter Health Sacramento Sierra Region a New Prescription for Efficient PC Support
Case Study Sutter Health Gains HIPAA-Compliant E-Mail Without Adding to IT Support Costs
Case Study Sutter Health Expands Electronic Health Records With HP
White Paper A Methodology for Modeling Front Office and Patient Care Processes in Ambulatory Health Care

Top results from Healthcare Services

Resource Center Protect your patient data and your budget at the same time
White Paper New HIPPA Regulations Require Quick Action By Group Health Plans
White Paper A Common Language Architecture for Health Care
White Paper A Digital Imaging Transformation in Radiology Departments
White Paper Alternative Health Care Models

» View all Healthcare Services listings

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement

Returning users: Log In Here!

Already registered on BNET, TechRepublic, or ZDNet? Simply log in.

Free Membership: Sign Up Now!

Sign up for a free membership today and get instant and unlimited access to one of the largest databases of white papers, webcasts, and casestudies anywhere. Your FREE membership allows you to:

  • Download an unlimited amount of content, including classic and current white papers, case studies, webcasts and more
  • Track content on your chosen topics of interest
  • Receive targeted email alerts when your favorite content is added
  • Save content for future reading
  • Receive our member newsletter

When you register to access this directory, you become a member of BNET. In addition, you allow us to share your information with companies that produce products or services featured in the library--so that such companies may contact you with information and offers regarding their products and services. This enables us to keep the library a free service. As a directory registrant, you will receive a complimentary subscription to the BNET member newsletter, The BNET Report. You can unsubscribe from this newsletter at any time. By clicking the Sign up button, you indicate that you agree to our Terms and Conditions and have read and understand our Privacy Policy (updated).